Market Overview

UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Related SGMO
Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge
15 Biggest Mid-Day Losers For Wednesday
Sangamo BioSciences' (SGMO) CEO Sandy Macrae on Q3 2016 Results - Earnings Call Transcript (Seeking Alpha)

Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.

Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."

Sangamo Biosciences closed at $8.82 on Friday.

Latest Ratings for SGMO

Oct 2016PiperJaffrayDowngradesOverweightNeutral
Aug 2016Janney CapitalDowngradesBuyNeutral
Dec 2015Janney CapitalInitiates Coverage onBuy

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Analyst Ratings


Related Articles (SGMO)

View Comments and Join the Discussion!